Main menu

Pages

$20 million sale of IP platform technology. Products & Targets Available at Walmart, Bed Bath & Beyond: Stock Symbol: CURR

featured image

CURR and Sera Labs

CURR & Nicole Kidman

CURR products

CURR Sera Topical

CURR film

$20 million sale of IP platform technology. Health and beauty line available at Walmart, Bed Bath & Beyond, CVS & Target.com: (Stock symbol: CURR)

CURE PHARMACEUTICAL HOLDING CORP (OTCMKTS:CURR)

CURR will host a conference call on Wednesday, August 3, 2022 at 5:00 pm EST to discuss the recent $20 million undiluted sale of a small portion of its product and intellectual property portfolio.”

— CURR

OXNARD, Calif., Aug. 1, 2022 /EINPresswire.com/ — A $20 million sale of IP platform technology. Health and Beauty line available at Walmart, Bed Bath & Beyond, CVS & Target.com: CURE Pharmaceuticals (Stock Symbol: CURR)

Proceeds will be used to grow CURR’s wellness and beauty brands and the rest of our proprietary platform technology

 Patented technology improves efficacy, safety and patient experience.

 25,000 square feet, FDA registered, NSF® cGMP certified manufacturing facility.

 Oral vitamin D supplements are more effective than standard supplements in achieving vitamin D sufficiency before and after surgery.

 The skincare line is available at select Walmart stores, CVS stores, and Bed Bath & Beyond stores.

 Oral thin film strips, Nutri-Strips™, on the shelves of CVS and Target.com.

 Partnership with Milagro Pharmaceuticals for registration and approval of Sildenafil oral thin film for ED treatment in Mexico.

 Patent approval for CUREfilm Blue™ technology for ED treatment.

CURR has sold certain of its platform technology intellectual property and related assets for a total consideration of $20 million. CURR will use a portion of its cash proceeds to repay certain debts and the remainder to grow its intellectual property portfolio and wellness and beauty brands. In addition, CURR retained remaining proprietary platform technology that it intends to monetize through technology commercialization or technology licensing or sales.

CURR will host a conference call on August 3, 2022 to provide shareholders with a complete corporate update. Conference call details will be published in a follow-up press release on August 1, 2022.

About CURR:

CURE Pharmaceutical (OTCQB: CURR) is a fully integrated, progressive drug delivery company. With quality and service as our top priority, the CURR team has extensive experience in formulating and manufacturing over-the-counter (OTC) products, pharmaceuticals and veterinary drugs, earning the trust and respect of customers around the world.

CURR is the pioneering developer of CUREform™, a patented drug delivery platform. This platform offers a number of proprietary immediate- and controlled-release drug delivery technologies designed to improve efficacy, safety and patient experience for a wide range of active ingredients. CURR delivery tech includes his CUREfilm®, advanced oral membrane. CUREdrops™ is an emulsion technology that can be incorporated into a variety of dosage forms (films, tinctures, beverages, etc.). CURR’s Unique Clinical Pipeline Includes His CUREfilm®Blue (sildenafil for treating erectile dysfunction), and CUREfilm®Kanna (THC and CBD).

As a vertically integrated company, CURR operates a 25,000 square foot FDA registered NSF.® Our cGMP certified manufacturing facility also allows us to partner with pharmaceutical and wellness companies around the world for private and white label production. CURR currently has partnerships in the United States, China, Mexico, Canada, Israel, and other European markets.

 Positive results from a study at Cincinnati Children’s Hospital Medical Center in which CURR’s proprietary oral thin film high dose vitamin D was administered to pediatric patients before and after hematopoietic stem cell transplantation

On May 12, CURR will launch CURR’s proprietary single-dose, oral, 40,000 IU vitamin D (brand name ImmunD3™ Nutri-Strips™ in the wellness retail market) in pediatric patients prior to stem cell therapy. announced positive results from a study conducted at the Cincinnati Children’s Hospital Medical Center. treatment. CURR’s oral vitamin D supplement was found to be more effective than standard supplements in achieving pre- and post-operative vitamin D sufficiency, which is important for reducing immune-mediated organ damage in children undergoing HSCT. It turns out.

For more information on this research, please see the poster presentation on the CURR website (https://curepharmaceutical.com/white-papers/).

 Products from CURR subsidiary Sera Labs Inc. now available at Walmart, Bed Bath & Beyond, CVS and Target.com

On April 14th, Sera Labs, a wholly owned subsidiary of CURR, announced that the Seratopical Revolution skincare line will be available at select Walmart stores, CVS and Bed Bath & Beyond stores. CURR has also placed innovative oral thin-film strips, Nutri-Strips™, on the shelves of his CVS and Target.com. Nutri-Strip technology is unique to Sera Labs and is the result of years of research and over 25 patents by the CURR development team.

 CURR and Milagro Pharmaceuticals collaborate for registration and approval to market sildenafil oral thin film in Mexico

On March 3, CURR and Milagro Pharmaceuticals, which seeks first-mover advantage in the targeted health and wellness markets through major collaborations, announced that CURR has announced the launch of a number of new drug delivery systems utilizing CUREform™, CURR’s patented drug delivery. Announced cooperation to register and market CURR OTC and pharmaceutical compounds in Mexico. Oral thin film (OTF) platform.

OTF products marketed and sold in Mexico through key distribution partners include:

CUREfilm Blue™ – an oral dissolving form of sildenafil citrate (the active ingredient in Viagra)®1) For the treatment of erectile dysfunction (ED).

Vitamin D3 – Provides a convenient 40,000 IU of Vitamin D per week

Electrolyte Energy Boost – Provides a healthier, sugar-free alternative to energy drinks

Sleep – A dose of melatonin that dissolves on the tongue and can be taken even after going to bed.

 Patent approval for CUREfilm Blue™ technology

On November 16, CURR announced that it had received a notice of issuance from the United States Patent Office (USPTO).

CUREfilm Blue™ leverages CURR’s patented and proprietary rapid-dissolving drug delivery platform known as CUREfilm™ to deliver the active pharmaceutical ingredient (API) sildenafil citrate.

For more information about CURE Pharmaceutical, Inc. (OTCQB: CURR), please visit www.curepharmaceutical.com and www.Seralabshealth.com.

Disclaimer 1: Products listed do not contain THC or comply with the 2018 Farm Bill.

Disclaimer 2: This article is purely for informational purposes and is not a recommendation to buy or sell stocks.

Mike Leddard
Cure Pharma Holding Co., Ltd.
extension 6176823625
email here
Visit us on social media:
Facebook
twitter
LinkedIn
other

Nicole Kidman’s Skincare Routine: @Susan Yara’s Reactions and Thoughts | #Skincare

.